Pascale Diesel and Lev Gerlovin, both vice presidents at Charles River Associates (CRA), describe the current capabilities and future potential of bioprinting alongside Andrew Thomson, an analyst in the life sciences practice at CRA.

Bioprinting has advanced rapidly over recent years through engineering step-changes in the use of 3D printing devices. With these developments, living cells can now be positioned layer-by-layer to produce functional tissue structures.

Key attributes of this emerging technology are that it is scalable and highly customisable, which facilitates the manufacturing of a large variety of tissues in an automated and repeatable way. These capabilities equip developers with tools to advance 3D-tissues for broad applications, from in vitro drug testing models, to therapeutic tissue implants to whole organ transplants. The bioprinting market is young, but it is close to producing engineered tissue products with high commercial potential.

Several companies (e.g. Organovo, Regenovo, BioDan, etc.) have had […]

Click here to view original web page at www.medicalplasticsnews.com